ACRO BIOMEDICAL CO., LTD.: 10-Q filed 2021-05-24
What ACRO BIOMEDICAL CO., LTD. reported in its quarterly report filed 2021-05-24 (fiscal Q1 2021): 24 published measures, 52 facts as tagged in accession 0001640334-21-001236.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-05-24
- Fiscal period
- fiscal Q1 2021
- Accession
- 0001640334-21-001236 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACRO BIOMEDICAL CO., LTD. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 938,874 | USD | |
| At 2020-12-31 | 998,053 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 309,997 | USD | |
| At 2020-12-31 | 312,185 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 628,877 | USD | |
| At 2020-12-31 | 685,868 | USD | |
| At 2020-03-31 | 879,796 | USD | |
| At 2019-12-31 | 798,239 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 24,359 | USD | |
| At 2020-12-31 | 18,123 | USD | |
| At 2020-03-31 | 10,636 | USD | |
| At 2019-12-31 | 911 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -59,494 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 81,116 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -8,380 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -26,014 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 14,616 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 35,739 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | -298,148 | USD | |
| At 2020-12-31 | -238,654 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 0 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 0 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -56,991 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 81,557 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 920,256 | USD | |
| At 2020-12-31 | 973,353 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 309,997 | USD | |
| At 2020-12-31 | 312,185 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 86,491 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 77,847 | USD | 91 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 868,000 | USD | |
| At 2020-12-31 | 938,000 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 29,500 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 159,404 | USD | 91 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 70,000 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 528,560 | USD | 91 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 86,491 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 77,847 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 47,760,000 | shares | |
| At 2020-12-31 | 47,760,000 | shares |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 18,618 | USD | |
| At 2020-12-31 | 24,700 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 18,358 | USD | |
| At 2020-12-31 | 24,500 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 0 | USD | |
| At 2020-12-31 | 0 | USD |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -2,503 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -441 | USD | 91 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 0 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 0 | USD | 91 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -70,000 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -528,560 | USD | 91 |
Inspect the source
- Entity
- ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
- Captured
- SEC response SHA-256
b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))